Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)

Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations.

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

The launch of Madrigal Pharmaceuticals Inc.’s NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now has a market cap of close to $8 billion.

There's a bright future ahead for this company.

Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%).

Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water.

The biotech could be worth a lot more in 10 years.

One player's minor pain is another's moderate gain.

Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations.

Will being the first to its market ensure that its future is bright?

Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs.

Its revenue ramp-up is just starting, and its market looks lucrative.